- Home
- PRIM vs TNGX Comparison
PRIM vs TNGX Comparison
Compare PRIM & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRIM | TNGX |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United States |
| Employees | N/A | 137 |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.5B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRIM | TNGX |
|---|---|---|
| Price | $86.65 | $28.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $155.20 | $21.78 |
| AVG Volume (30 Days) | 1.9M | ★ 4.5M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 51.66 | 26.89 |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $9.92 | N/A |
| Revenue Next Year | $8.80 | N/A |
| P/E Ratio | $275.38 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $65.00 | $5.60 |
| 52 Week High | $205.50 | $34.39 |
Technical Indicators
Market Signals| Indicator | PRIM | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 50.17 |
| Support Level | $65.00 | $28.13 |
| Resistance Level | $99.29 | $33.96 |
| Average True Range (ATR) | 3.99 | 2.01 |
| MACD | 0.90 | -0.46 |
| Stochastic Oscillator | 14.13 | 27.89 |
Price Performance
Historical ComparisonAbout PRIM Primoris Services Corporation
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.